Form 4: Director Homcy Acquires Maze Therapeutics Shares

Maze Therapeutics Director Charles J. Homcy received 1,489 shares of common stock through a pro rata distribution from Third Rock Ventures affiliates.

Summary

• Charles J. Homcy, a Director of Maze Therapeutics, Inc., acquired 1,489 shares of the company's common stock.
• The transaction occurred on November 19, 2025, and involved no monetary consideration.
• The shares were received as a pro rata distribution from entities affiliated with Third Rock Ventures.
• This distribution was made in accordance with the exemption afforded by Rule 16a-9 of the Securities Exchange Act of 1934.
• Following this transaction, Mr. Homcy directly beneficially owns 31,113 shares of common stock.
• An additional 7,422 shares are indirectly beneficially owned by the Charles J. Homcy Revocable Trust UA 11/4/1998, for which Mr. Homcy serves as trustee.

Sentiment

Score: 5

Explanation: The filing is a factual report of an insider transaction, not a performance report, and thus carries a neutral sentiment.

Positives

• An insider, Director Charles J. Homcy, increased his beneficial ownership of Maze Therapeutics, Inc. common stock by 1,489 shares.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

This filing is a routine disclosure of an insider's change in beneficial ownership, common in the biotechnology or pharmaceutical industry for companies like Maze Therapeutics. It does not provide broader industry trends or competitive analysis.

Comparison to Industry Standards

• This Form 4 filing reports a standard insider transaction as required by SEC regulations. There are no specific results to compare against global benchmarks or comparable companies/projects.

Related Party Transactions

• The acquisition of 1,489 shares was a pro rata distribution from entities affiliated with Third Rock Ventures, which could be considered a related party transaction.

Stakeholder Impact

• Minimal impact on shareholders, employees, customers, suppliers, or creditors, as this is a routine disclosure of an insider's share acquisition through a distribution, not a market purchase or a significant corporate event.

Key Dates

Keywords

Maze Therapeutics, MAZE, Form 4, insider transaction, beneficial ownership, common stock, director, Charles J. Homcy, Third Rock Ventures, stock acquisition